Eupraxia pharmaceuticals inc EPRX.US 總覽分析
EPRX 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足,尚無法提供評分
EPRX 近期報酬表現
3.76%
Eupraxia pharmaceuticals inc
3.56%
同產業平均
1.47%
S&P500
與 EPRX 同產業的標的表現
- EXEL Exelixis, inc.價值 4 分趨勢 4 分波段 4 分籌碼 4 分股利 1 分查看更多
EPRX 公司資訊
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company's lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.